Chengde Jingfukang Pharmaceutical Group Co., Ltd. has experienced a stormy journey for nearly 6 years, and has made great progress in the past 3 years of reform and opening up. Under the wise decision of Li Shenming, the chairman and general manager at the helm, and under the leadership of a strategic plan, the company has developed into a modern large-scale enterprise group integrating science, industry and trade, and has successively entered the top 5 pharmaceutical industrial enterprises in China, the top 5 Chinese medicine industries in China, and the top 1 taxpayers in China, ranking 3 in Hebei.
the group company is composed of Chengde jingfukang pharmaceutical investment company, China medicinal materials group company and Shanghai fosun pharmaceutical group, and three shareholders. In addition to the headquarters, the group company also owns several well-established industrial and commercial pharmaceutical enterprises such as Chifeng Danlong Pharmaceutical Company (Danlong Pharmaceutical Company), Chifeng Jingfukang Pharmaceutical Co., Ltd., Chengde Jingfukang Pharmaceutical Co., Ltd., Chengde Tianhe Pharmaceutical Co., Ltd., Chifeng Rongxingtang Medicinal Materials Company, etc., and has formed an integrated model of Chinese herbal medicine cultivation, Chinese patent medicine research and development, production and sales.
the company has advanced production technology and perfect quality control system, and has production lines of various dosage forms such as granules, capsules, tablets, oral liquids, soft capsules and tinctures. The company has computer-controlled extraction production line, Japanese dry granulation production line and German automatic packaging production line. It can produce more than 2 kinds of products, among which Jingfukang Granules, Yaotongning Capsules, Compound Shiwei Tablets, Qinggong Changchun Capsules, etc. are protected varieties of traditional Chinese medicine, Jingfukang Granules are also included in the national secret technology project, Yaotongning Capsules are the first large compound drug to be taken orally by adopting the fingerprint control technology, Jingfukang Granules, Yaotongning Capsules and Compound Shiwei Tablets are included in the 21 edition of the National Pharmacopoeia, and the single varieties of Jingfukang Granules and Yaotongning Capsules are sold every year.
the company's marketing network covers 31 provinces, municipalities, autonomous regions and municipalities directly under the central government, and is exported to Hong Kong, Macao, Southeast Asia, Europe and the United States, and is deeply trusted and praised by consumers and users.